COMBINATION OF BEVACIZUMAB, IRINOTECAN AND TEMOZOLOMIDE FOR RELAPSED OR REFRACTORY NEUROBLASTOMA: A PHASE II STUDY.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 May 2018
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 01 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 01 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 01 Aug 2017 Results (n=33) assessing safety and response rates, published in the Pediatric Blood and Cancer.